Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody.

"Asthma can be a very debilitating disease, and despite current therapies, patients are in need of novel treatment options," said Nestor Molfino, M.D., vice president, clinical development, pulmonary disease. "Some asthmatics may show an increased circulation of eosinophils in blood -- a certain type of white blood cell believed to play a critical role in the severity and disease pathway of asthma; therefore administration of this antibody may increase asthma control."

MEDI-563, which was generated using BioWa's POTELLIGENT(TM) Technology platform, has previously been investigated in a Phase 1 open-label dose-escalating study to evaluate the safety and tolerability of a single intravenous infusion in adults with mild-to-moderate asthma. Data from the completed Phase 1 study demonstrated that the antibody was well-tolerated with biologic activity producing substantial and prolonged depletion of blood eosinophils, thus supporting its continued development. Published literature suggests that reduction of eosinophils in sputum was associated with better asthma control and increases in sputum eosinophilia were associated with exacerbations of asthma. The antibody is also currently being evaluated in a double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability and effects of the antibody on airway eosinophils in adults with asthma.

About Interleukin-5 Receptor (IL-5R)

Interleukin-5 is a cytokine secreted predominantly
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
(Date:5/5/2015)... Washington, and WASHINGTON, D.C., USA (PRWEB) May 05, 2015 ... on U.S. export regulations covering a wide range of ... industry say are hampering global competitiveness of U.S. industry. ... host a webinar on 12 May on ... XII, which governs the commodities covered by International Traffic ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... SOUTH SAN FRANCISCO, Calif. , May 5, 2015 ... for the treatment of cancer, today announced that ... present at the Credit Suisse Antibody Day in ... on Wednesday, May 6. Dr. McCarthy will present an ... cancer immunotherapy and Probody drug conjugate programs. ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... May 11, 2011 SeraCare Life Sciences, Inc. (NASDAQ: ... providing vital products and services to facilitate the discovery, ... announced the election of Joseph Nemmers and Kevin Hrusovsky ... Mr. Nemmers has been appointed to the position of ...
... NEW YORK, May 11, 2011 ... new market research report is ... Biotech M&A and ... are Poised to Increase in ...
... 7, 2011) Research being presented at Digestive ... significantly increased benefits for qualifying patients undergoing bariatric ... to be considered when determining whether the surgery ... international gathering of physicians and researchers in the ...
Cached Biology Technology:SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors 2SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors 3SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors 4Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 2Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 3Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 4Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 5Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 6Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 7Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 8Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 9Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 10Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 11Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines 12New approaches, technological advances offer promise for obesity treatment 2
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Researchers in the Department of Physics and Astronomy ... synthesis method, which has led them to the discovery ... the uptake of drugs by the body,s cells. ... of the new method is the independent control of ...
... at the Sahlgrenska Academy, University of Gothenburg, Sweden, have ... involving the stomach hormone ghrelin. When ghrelin,s actions in ... system are reduced. It is an important discovery that ... alcohol dependence. The results will be published in ...
... to produce high-resolution fluorescence images from this depth because of ... journal, the Munich researchers describe how they can reveal ... to light". In the future this technology may facilitate the ... Since the dawn of the microscope scientists have been using ...
Cached Biology News:University of Leicester researchers discover new fluorescent silicon nanoparticles 2Discovery may provide new treatments for alcohol dependence 2The sound of light: Innovative technology shatters the barriers of modern light microscopy 2
... Analysis Note: Assays in Tris buffer, ... in the glycine buffer system. Assays in ... 5X that of the glycine buffer system. ... powder containing Tris-citrate buffer salts Preparation Unit ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... The Jouan RCT series of refrigerated cold ... to trapping of low volatility/aqueous solvents or ... RC10 and other vacuum concentrators/centrifugal evaporators. Also ... cooling systems such as used in electron ...
96 Well Plate UB, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: